Raymedica, the Pioneer in Nucleus Arthroplasty, today announced it will present first phase clinical results from a 10-patient clinical evaluation of it’s new HydraFlex Nucleus Arthroplasty System™ at the 7th Annual Spine Arthroplasty Society (SAS7) Conference in Berlin, Germany. Raymedica is evaluating the benefits of the HydraFlex Technology for patients with early degenerative disc disease. The clinical evaluation, conducted in Mexico City by Alejandro Reyes-Sanchez, MD, at the Instituto Nacional de Rehabilitaci³n will be presented at the Raymedica SAS7 Workshop, May 2nd, Salon 16, Riga Room at 12:35 PM.
“We are pleased with the benefits that the patients receiving the HydraFlex Technology have achieved in our clinical evaluation; the results of clinical benefit and radiological findings suggest the HydraFlex technology is providing the benefits we were expecting in comparison to other currently available treatments,” stated, Alejandro Reyes-Sanchez, MD, Chief of the Spine Division, Instituto Nacional de Rehabilitaci³n. “We will continue to carefully analyze the clinical data to determine the next steps in further advancing this technology into greater clinical applications.”
“Raymedica is committed to ensuring that physicians have the most advanced treatments to offer their patients that don’t compromise safety or the patient’s quality of life,” said John J. Viscogliosi, Chairman and Chief Executive Officer of Raymedica, LLC. “We continue to invest in research and clinical studies to expand our Nucleus Arthroplasty Technology portfolio, a non-fusion technology for the treatment of patients with early degenerative disc disease. We are excited to share at SAS7 the clinical results of the HydraFlex Technology performed by an industry leading physician, Dr. Reyes-Sanchez.”
About Raymedica
Raymedica, based in Minneapolis, Minnesota, is the Pioneer in Nucleus Arthroplasty having developed the world’s first nucleus replacement device in 1996. Raymedica develops, manufactures and markets medical device systems designed to treat patients with degenerative disc disease that have been unresponsive to non-surgical treatment. Raymedica’s products are currently available in many countries worldwide, but are limited to investigational use only in the United States. For more information, visit the Company’s website at http://www.raymedica.com.
Comments